Javascript must be enabled to continue!
Possible Synergistic Modulation of Hormonal Balance and Ovarian Structure by Clomiphene–Letrozole Co-Administration in a Rodent Model of Hyperandrogenism
View through CrossRef
Abstract
Infertility, defined as the inability to achieve pregnancy after 12 months of unprotected intercourse, is a major reproductive health concern. In females, hyperandrogenism often contributes to polycystic ovarian syndrome (PCOS), a leading cause of infertility. Although clomiphene and letrozole are widely used as ovulation inducers, their individual efficacy is limited, and the potential benefit of combined therapy remains unclear. This study investigated the effects of clomiphene–letrozole co-administration on gonadotrophic hormones, inflammatory cytokines, antioxidant status, and ovarian histomorphology in a rat model of hyperandrogenism. Thirty female Wistar rats were randomised into five groups (n=6). Group A received saline, while groups B–E were administered testosterone enanthate (10 mg/kg, subcutaneous injection) for 35 days to induce PCOS. Group B served as PCOS control, while groups C, D, and E were additionally treated with clomiphene (100 µg/kg), letrozole (5 mg/kg), or their combination, respectively, for 10 days from day 36. Hormonal assays, cytokine profiling, antioxidant measurements, and ovarian histology were performed. Results showed that the co-administration significantly reduced body and ovary weights, lowered glucose levels, and improved oestradiol and follicle-stimulating hormone profiles compared with PCOS controls. Combination therapy also enhanced antioxidant capacity, reduced lipid peroxidation, and modulated inflammatory cytokines by lowering IL-1β and TNF-α while elevating IL-10. Histological evaluation revealed cystic follicles with basement membrane thickening in the PCOS control, consistent with ovarian hyperstimulation; and a reversal with clomiphene and or letrozole treatment. In conclusion, clomiphene–letrozole co-administration demonstrated superior benefits over monotherapy in modulating endocrine, oxidative, and inflammatory parameters, suggesting a potential therapeutic advantage in ovulation induction for PCOS-related infertility.
Title: Possible Synergistic Modulation of Hormonal Balance and Ovarian Structure by Clomiphene–Letrozole Co-Administration in a Rodent Model of Hyperandrogenism
Description:
Abstract
Infertility, defined as the inability to achieve pregnancy after 12 months of unprotected intercourse, is a major reproductive health concern.
In females, hyperandrogenism often contributes to polycystic ovarian syndrome (PCOS), a leading cause of infertility.
Although clomiphene and letrozole are widely used as ovulation inducers, their individual efficacy is limited, and the potential benefit of combined therapy remains unclear.
This study investigated the effects of clomiphene–letrozole co-administration on gonadotrophic hormones, inflammatory cytokines, antioxidant status, and ovarian histomorphology in a rat model of hyperandrogenism.
Thirty female Wistar rats were randomised into five groups (n=6).
Group A received saline, while groups B–E were administered testosterone enanthate (10 mg/kg, subcutaneous injection) for 35 days to induce PCOS.
Group B served as PCOS control, while groups C, D, and E were additionally treated with clomiphene (100 µg/kg), letrozole (5 mg/kg), or their combination, respectively, for 10 days from day 36.
Hormonal assays, cytokine profiling, antioxidant measurements, and ovarian histology were performed.
Results showed that the co-administration significantly reduced body and ovary weights, lowered glucose levels, and improved oestradiol and follicle-stimulating hormone profiles compared with PCOS controls.
Combination therapy also enhanced antioxidant capacity, reduced lipid peroxidation, and modulated inflammatory cytokines by lowering IL-1β and TNF-α while elevating IL-10.
Histological evaluation revealed cystic follicles with basement membrane thickening in the PCOS control, consistent with ovarian hyperstimulation; and a reversal with clomiphene and or letrozole treatment.
In conclusion, clomiphene–letrozole co-administration demonstrated superior benefits over monotherapy in modulating endocrine, oxidative, and inflammatory parameters, suggesting a potential therapeutic advantage in ovulation induction for PCOS-related infertility.
Related Results
Induced-hyperandrogenism in female rats: assessing possible modulation of neurobehavioural and neurotransmitter changes following clomiphene/letrozole intervention
Induced-hyperandrogenism in female rats: assessing possible modulation of neurobehavioural and neurotransmitter changes following clomiphene/letrozole intervention
Abstract
Hyperandrogenism is the excessive production of androgenic hormones resulting in infertility in a number of women. While letrozole and clomiphene citrate h...
P-604 A novel ovulation induction regimen in women with polycystic ovary syndrome resistant to letrozole: letrozole stair-step duration regimen
P-604 A novel ovulation induction regimen in women with polycystic ovary syndrome resistant to letrozole: letrozole stair-step duration regimen
Abstract
Study question
Whether the letrozole stair-step duration regimen is effective and time-saving for ovulation induction i...
Comparison of Clomiphene Citrate and Letrozole in induction of ovulation among patients with PolyCystic Ovarian syndrome (PCOS) Primary Sub-fertility
Comparison of Clomiphene Citrate and Letrozole in induction of ovulation among patients with PolyCystic Ovarian syndrome (PCOS) Primary Sub-fertility
Objective: To compare the efficacy of clomiphene and Letrozole in the induction of ovulation in patients with primary ovarian sub-fertility.
Methodology: This was a Randomized co...
Low dose-extended letrozole versus double dose-short letrozole protocol for ovulation induction in polycystic ovary syndrome
Low dose-extended letrozole versus double dose-short letrozole protocol for ovulation induction in polycystic ovary syndrome
Background: Letrozole, an aromatase inhibitor has been regarded as the first line drug for ovulation induction in anovulatory PCOS patients because of its monofollicular growth and...
P-605 The predictive role of follicle-stimulating hormone receptor polymorphism on letrozole resistance in women with polycystic ovary syndrome
P-605 The predictive role of follicle-stimulating hormone receptor polymorphism on letrozole resistance in women with polycystic ovary syndrome
Abstract
Study question
Whether follicle stimulating hormone receptor (FSHR) polymorphism can predict letrozole resistance in wo...
PREGNANCY ACHIEVEMENT USING LETROZOLE VERSUS CLOMIPHENE CTTRATE IN ANOVULATORY WOMEN WITH POLYCYSTTC OVARIAN SYNDROME
PREGNANCY ACHIEVEMENT USING LETROZOLE VERSUS CLOMIPHENE CTTRATE IN ANOVULATORY WOMEN WITH POLYCYSTTC OVARIAN SYNDROME
Background: The most prevalent type of anovulatory infertility that occurs in women of reproductive age is polycystic ovarian syndrome (PCOS). Clomiphene citrate has been used in o...
Unexplained Infertility: Comparison of Efficacy of Letrozole and Clomiphene Citrate
Unexplained Infertility: Comparison of Efficacy of Letrozole and Clomiphene Citrate
Background: Infertility is always been considered as social issue because of its impact on individuals as well as on families. Unexplained infertility defined as inability of a cou...
Comparison of letrozole and clomiphene citrate efficacy in terms of ovulation induction and pregnancy rate.
Comparison of letrozole and clomiphene citrate efficacy in terms of ovulation induction and pregnancy rate.
Objective: To compare the efficacy of Letrozole and clomiphene citrate in Patients of Anovulation polycystic ovarian syndrome with Infertility. Study Design: Randomized Controlled ...

